Dr Megan Berry brings a compassionate and patient-centred approach to her care. She places a strong emphasis on clear communication and taking time to understand her patients’ preferences and concerns to ensure they feel heard, supported and empowered at every step of their journey. She is passionate about continuously improving the quality of care delivered to patients, through an active involvement in medical education, clinical research and trials.
Dr Megan Berry is an experienced radiation oncologist at Icon Cancer Centre Revesby. In 2005, she completed a Bachelor of Medical Sciences and Bachelor of Medicine, Bachelor of Surgery (BSc (Med) MBBS) at the University of New South Wales (UNSW). In recognition of her leadership and fellowship throughout the program, she was the recipient of the UNSW Foundation Year Graduates Medal. Dr Berry subsequently completed specialist radiation oncology training with the New South Wales Southern Training Network and became a fellow of the Royal Australian and New Zealand College of Radiologists (FRANZCR).
Since 2013, Dr Berry has held an appointment as radiation oncology Staff Specialist at the Liverpool, Bankstown-Lidcombe and Campbelltown Hospitals. During this tenure, she has gained extensive experience in the management and treatment of genitourinary, gynaecological, gastrointestinal, head and neck, skin, breast and lung cancers, and the use of spine, bone and nodal stereotactic ablative radiation therapy (SABR).
Dr Berry is committed to continuously improving the quality of care delivered to patients living with cancer. Alongside her current appointments, she is Director of Training for radiation oncology at Liverpool and Campbelltown Hospitals and regularly participates in medical education, clinical research and trials. She is also an active member of various breast cancer, lung cancer, geriatric oncology and cancer pain multidisciplinary care teams (MDTs).
Her clinical experience covers a wide range of solid tumour malignancies, with a special interest in breast cancer, lung cancer and stereotactic radiation therapy.